News | August 03, 2024
AbbVie completes acquisition of Cerevel Therapeutics
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
Granules now has a total of 58 ANDA approvals from US FDA
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Acetazolamide is used to treat glaucoma
Gabapentin Tablets are indicated for management of postherpetic neuralgia in adults
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
Topiramate Extended-Release capsule had annual sales of US $68.8 mn in the United States according to IQVIA data (IQVIA MAT Sep 2022)
Subscribe To Our Newsletter & Stay Updated
